LLY

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 1997, for Eli Lilly & Co, a pharmaceutical and life-sciences company headquartered in Indianapolis, Indiana. The report includes unaudited consolidated financial statements for the three and six months ended June 30, 1997, compared to the same periods in 1996.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 17% in Q2 1997 and 13% for the six-month period compared to 1996. Growth was driven by volume increases (19% in Q2) and new product launches, partially offset by unfavorable exchange rates (-3%).
• Asset Impairment: The company recorded a non-cash impairment charge of $2,443.0 million in Q2 1997 related to the PCS health-care-management business. This charge reduced the carrying value of long-lived assets to their estimated fair value of $1.5 billion due to slower-than-expected industry trends and unrealized strategic partnership opportunities.
• Gain on Sale: The company sold its 40% interest in the DowElanco joint venture to The Dow Chemical Company for $1.2 billion, recognizing a pre-tax gain of $618.2 million.
• Profitability: Despite strong operational performance, the reported net loss was driven by the $2.4 billion impairment charge. Excluding the impairment and the DowElanco gain, Q2 1997 net income would have been $417.2 million, a 21% increase over Q2 1996.
• Product Performance: Sales of newer products Zyprexa ($156.0M in Q2), ReoPro ($59.8M in Q2), and Gemzar ($41.0M in Q2) drove pharmaceutical growth. Prozac sales increased 11% in Q2 to $597.6 million. Conversely, anti-infective sales declined 14% due to generic competition.

Guidance, Outlook, and Risks

• Outlook: Management expects R&D spending to increase 14-17% in 1997. Marketing and administrative expenses are expected to grow at a rate less than sales growth in the second half of the year. The company anticipates cost of sales as a percent of sales will approximate 1996 levels for the full year.
• Liquidity: Cash generated from operations, combined with available cash and the proceeds from the DowElanco sale, is deemed sufficient to fund 1997 operating needs, debt service, capital expenditures, and dividends.
• Legal Contingencies:
  • Prozac Patent Litigation: Barr Laboratories and Geneva Pharmaceuticals have filed applications for generic Prozac, asserting Lilly's patents are invalid. Lilly has sued both parties. An unfavorable outcome could materially adversely affect financial position.
  • Pricing Litigation: The company settled a significant portion of retail pharmacy pricing litigation in Q2 1997. Related state and federal cases remain pending.
  • Product Liability: Ongoing lawsuits involving diethylstilbestrol and Prozac. The company has accrued for estimated exposure, with the majority of costs expected to be covered by insurance.
• Accounting Changes: The company will adopt SFAS No. 128 (Earnings per Share) in Q4 1997, requiring restatement of prior periods to present basic and diluted EPS. This is not expected to materially impact reported EPS.

Investor Verification Checklist

• Verify the sustainability of sales growth for new products (Zyprexa, ReoPro, Gemzar) versus the decline in anti-infectives due to generic competition.
• Assess the potential financial impact of the pending Prozac patent litigation against Barr and Geneva.
• Review the status of the PCS health-care-management business and the likelihood of future strategic partnerships or divestitures.
• Monitor the resolution of retail pharmacy pricing litigation and potential additional accruals.
• Confirm the company's ability to maintain liquidity and credit ratings following the large non-cash impairment charge.